Previously recorded as Cerecor, Inc. (to 2022)
6 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2034. from the record
Of the 4 now held by other companies, 3 name Merck Sharp and Dohme LLC as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2034
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2036 · High confidence
Also notable
Ends May 2041 · High confidence
Also notable
Ends no later than Jan 2034 · Low confidence
Also notable
Ends Nov 2043 · High confidence
Nucleic Acid Prodrugs
US 10,745,435
Granted 2020. Computed term ends 2036.
A Method of Treating Acute Respiratory Distress Syndrome (ARDS) or Acute Lung Injury (ALI) Associated with COVID-19 by Administering an anti-LIGHT Antibody
US 11,708,406
Granted 2023. Computed term ends 2041.
Inhalation Devices and Systems and Methods Including the Same
US 10,245,396
Granted 2019. Computed term ends 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Method of Treating Conditions Associated with Elevated INTERLEUKIN-18 (IL-18) by Administering an ANTI-IL-18 Antibody
US 12,799,190
Granted 2026. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Dec 2035 · High confidence
The largest patent family in this portfolio, 5 related applications, renewed at 2 of 3 maintenance windows. Protection runs to 2035.
now held by Merck Sharp & Dohme LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for A Method of Treating Acute Respiratory Distress Syndrome (ARDS) or Acute Lung Injury (ALI) Associated with COVID-19 by Administering an anti-LIGHT Antibody (US 11,708,406) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,245,396 | Inhalation Devices and Systems and Methods Including the Same In force · Low confidence | In force | Low confidence | |
| US 10,745,435 | Nucleic Acid Prodrugs In force · High confidence | In force | High confidence | |
| US 11,479,576 | Nucleic Acid Prodrugs In force · High confidence | In force | High confidence | |
| US 12,331,107 | Methods of Treating Pneumonia or Respiratory Failure Associated with COVID-19 by Administering an Anti-Light Antibody In force · Low confidence | In force | Low confidence | |
| US 11,708,406 | A Method of Treating Acute Respiratory Distress Syndrome (ARDS) or Acute Lung Injury (ALI) Associated with COVID-19 by Administering an anti-LIGHT Antibody In force · High confidence | In force | High confidence | |
| US 12,799,190 | Method of Treating Conditions Associated with Elevated INTERLEUKIN-18 (IL-18) by Administering an ANTI-IL-18 Antibody In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 4 patents in force now held by others · 6 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.